Your browser doesn't support javascript.
loading
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
Antonio Buendía, Jefferson; Patiño, Diana Guerrero.
Afiliação
  • Antonio Buendía J; Research Group in Pharmacology and Toxicology "Infarto". Department of Pharmacology and Toxicology. University of Antioquia, Universidad de Antioquia, Medellín, Colombia.
  • Patiño DG; Deparment of Child Health, Hospital Infantil Concejo de Medellín, Colombia.
Expert Rev Pharmacoecon Outcomes Res ; 22(4): 575-580, 2022 Jun.
Article em En | MEDLINE | ID: mdl-34860616
INTRODUCTION: Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits IL-4 and IL-13 signaling. This drug raises concerns about the economic impact in scenarios with constrained resources. This study aimed to estimate the cost-utility of dupilumab plus standard care (SoC) vs SoC alone in adolescents and adults with severe asthma and eosinophilic phenotype. METHODS: A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with uncontrolled allergic asthma in Colombia. Total costs and QALYs of standard therapy (ICS + LABA), add-on therapy with dupilumab, were calculated over a lifetime horizon. Multiple sensitivity analyses were conducted. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of $19,000. RESULTS: The base-case analysis showed dupilumab was associated with higher annual annual per-patient costs (US$5,719 for dupilumab and US$1,214 for standard therapy) and higher QALYs than standard therapy (fe  4.06 QALYs vs 3.97 QALYs, respectively). . The incremental cost-effectiveness ratio estimated was US$50,160 per QALY gained. CONCLUSION: Dupilumab is not cost-effective using a WTP of US$19000 per QALY threshold in Colombia. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines and should be replicated to validate their results in other middle-income countries.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Anticorpos Monoclonais Humanizados Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Adolescent / Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos / Anticorpos Monoclonais Humanizados Tipo de estudo: Guideline / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Adolescent / Humans País/Região como assunto: America do sul / Colombia Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Reino Unido